Upsher-Smith Laboratories reported its parent company, Japan-based Sawai Pharmaceutical has entered into an exclusive agreement with AstraZeneca to manufacture and market Zomig (zolmitriptan) Tablets 2.5 mg and Zomig (zolmitriptan) Rapid Melt (RM) Tablets 2.5 mg, a migraine medication in Japan. The Rapid Melt or RM preparation is designed to melt quickly in the mouth, due to the actions of disintegrating and foaming agents within the product, whether taken with or without water. Under the terms of the agreement, Sawai is expected to take over the manufacturing and marketing of the products in Japan by mid-2018 from AstraZeneca K.K.